UTHR logo

UTHR United Therapeutics Corporation

NASDAQ Global Select · Biotechnology · Healthcare

$554.73
-4.37 (-0.78%)

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pul…

Market Cap: $23.63Bwww.unither.com

Price

No data yet.

Social Signal Score

50
5d
50
1 mentions
—
30d
50
8 mentions
—
60d
49
24 mentions
—
90d
52
35 mentions
—
news: 23 · rss: 10 · marketaux: 2

Analyst Ratings

31 analysts
Buyconsensus
Strong Buy 0Buy 18Hold 12Sell 1Strong Sell 0
Avg price target$671.73+21.1%
Low $368Median $703High $850
Current Consensus

Revenue

$832.50M+103.55%
$311.10M$484.90M$658.70M$832.50M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$27.48
$26.29–$28.65
10 analysts
FY2026
$24.65-10% YoY
$21.70–$26.99
11 analysts
FY2027
$29.78+21% YoY
$25.64–$37.05
11 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Martine A. Rothblatt
Sector
Healthcare
Industry
Biotechnology
Employees
1,400
Beta
0.56
Country
US
Piotroski score
7 / 9 (Strong)
Altman Z-score
22.11
www.unither.com